VIVS
VivoSim Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.28
−0.29%Aug 21, 2026, 00:00 UTC
VivoSim Labs, Inc. received a notice from NASDAQ on August 17, 2026, stating that the company is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share, and the company has until February 16, 2027, to regain compliance.
Jul 21, 2026, 12:05 UTC
VivoSim enters the Chinese market with the first commercial sales of its NAMkind™ toxicology screening and efficacy testing services.
Source:Jul 17, 2026, 00:00 UTC
VivoSim Labs, Inc. signed a private placement agreement to sell pre-funded warrants and common warrants for its common stock to an undisclosed healthcare-focused institutional investor, with A.G.P./Alliance Global Partners acting as placement agent, for gross proceeds of approximately $4.0 million.
Source:Jul 15, 2026, 12:05 UTC
VivoSim Labs, Inc. announced that it received a $5 million milestone payment from Eli Lilly.
Source: